NEW
YORK, June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law
firm, is investigating whether certain officers and directors of
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached
their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Actinium
Pharmaceuticals caused the company to misrepresent or fail to
disclose that (1) the Company's data from the Sierra Trial was
unlikely to satisfy the FDA's guidelines for the acceptance and
approval of Iomab-B BLA; (2) the additional analyses, including
long-term follow-ups that purportedly demonstrated a trend towards
improved Overall Survival that the Company provided to the FDA in
an attempt to mitigate Sierra's poor OS data were unlikely to
satisfy the FDA's guidelines for the acceptance and approval of
Iomab-B BLA; (3) as a result, the FDA would likely refuse to review
the Iomab-B BLA or, if it did consider that BLA, that the
application in its current form was unlikely to be approved; and
(4), as a result, positive statements about the Company's business,
operations, and prospects were materially misleading and/or lacked
a reasonable basis.
If you currently own ATNM and purchased prior to October 31, 2022
please contact Justin Kuehn,
Esq. here, by email at justin@kuehn.law or
call (833) 672-0814. Kuehn
Law pays all case costs and does not charge its investor
clients. Shareholders should contact the firm immediately as
there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved,
you contribute to the integrity and fairness of the financial
markets. Your investment. Your voice. Your
future.™
For additional information, please visit Shareholder Derivative
Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar
outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-actinium-pharmaceuticals-inc-to-contact-law-firm-302477892.html
SOURCE Kuehn Law, PLLC
